Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial-Reference-Cited by-同舟云学术

Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial

Published:2021-03-18 Issue:4 Volume:18 Page:825-834
ISSN:1612-9059
Container-title:Esophagus
language:en
Short-container-title:Esophagus

Author:

Shiraishi Osamu,Makino Tomoki^ORCID,Yamasaki Makoto,Tanaka Koji,Yamashita Kotaro,Ishida Tomo,Sugimura Keijiro,Miyata Hiroshi,Motoori Masaaki,Fujitani Kazumasa,Takeno Atsushi,Hirao Motohiro,Kimura Yutaka,Satoh Taroh,Yano Masahiko,Doki Yuichiro,Yasuda Takushi

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

https://link.springer.com/content/pdf/10.1007/s10388-021-00831-3.pdf

Reference31 articles.

1. Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M. Gastroenterological surgery in Japan: the past, the present and the future. Ann Gastroenterol Surg. 2017;1(1):5–10.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics 2011. CA Cancer J Clin. 2011;61(2):69–90.

3. Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR, Lara A, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236(3):376–84 (discussion 384–375).

4. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

5. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V. Australasian gastro-intestinal trials G: survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of Initial Tumor Reduction as a Prognostic Factor in Esophageal Squamous Cell Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery;Annals of Surgical Oncology;2024-04-25

2. Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta‐analysis;Cancer Medicine;2024-02

3. Indications for neoadjuvant chemotherapy in older patients undergoing esophagectomy for esophageal cancer;Surgery Today;2023-10-31

4. 切除可能進行食道癌に対する術前DTX+CDDP+5-FU療法2コースの有用性の検討;The Japanese Journal of Gastroenterological Surgery;2023-07-01

5. Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial;Journal of Translational Medicine;2023-06-24